

Beata J Stanisz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9389231/publications.pdf>

Version: 2024-02-01

40
papers

952
citations

686830

13
h-index

454577

30
g-index

41
all docs

41
docs citations

41
times ranked

1329
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Simple modification of titanium(IV) oxide for the preparation of a reusable photocatalyst. <i>Materials Science and Engineering B: Solid-State Materials for Advanced Technology</i> , 2022, 276, 115559. | 1.7 | 10 |
| 2 | Genotoxic impurities in pharmaceutical products – regulatory, toxicological and pharmaceutical considerations. <i>Journal of Medical Science</i> , 2021, 90, e502. | 0.2 | 0 |
| 3 | Titanium Dioxide-Based Photocatalysts for Degradation of Emerging Contaminants including Pharmaceutical Pollutants. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8674. | 1.3 | 34 |
| 4 | Solid-State Stability Profiling of Ramipril to Optimize Its Quality Efficiency and Safety. <i>Pharmaceutics</i> , 2021, 13, 1600. | 2.0 | 3 |
| 5 | Phthalocyanine-Grafted Titania Nanoparticles for Photodegradation of Ibuprofen. <i>Catalysts</i> , 2020, 10, 1328. | 1.6 | 12 |
| 6 | Lignin-Based Spherical Structures and Their Use for Improvement of Cilazapril Stability in Solid State. <i>Molecules</i> , 2020, 25, 3150. | 1.7 | 7 |
| 7 | Titanium Dioxide Nanoparticles in Food and Personal Care Products – What Do We Know about Their Safety?. <i>Nanomaterials</i> , 2020, 10, 1110. | 1.9 | 126 |
| 8 | Titanium Dioxide Nanoparticles: Prospects and Applications in Medicine. <i>Nanomaterials</i> , 2020, 10, 387. | 1.9 | 333 |
| 9 | Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs. <i>Pharmacological Research</i> , 2019, 147, 104326. | 3.1 | 8 |
| 10 | Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing. <i>Drug Discovery Today</i> , 2019, 24, 1059-1065. | 3.2 | 28 |
| 11 | Does Polyvinylpyrrolidone Improve the Chemical Stability of Cilazapril in Solid State?. <i>Iranian Journal of Pharmaceutical Research</i> , 2019, 18, 579-595. | 0.3 | 4 |
| 12 | Can angiotensin-converting enzyme inhibitors interfere with the free radicals? Measurement of antioxidant capacity using DPPH radical reduction examined by UV-VIS method. <i>Acta Poloniae Pharmaceutica</i> , 2019, 76, 233-239. | 0.3 | 1 |
| 13 | Synthesis, in vitro and in silico evaluation of novel trans -stilbene analogues as potential COX-2 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 141-151. | 1.4 | 22 |
| 14 | Impact of hydrochlorothiazide on the stability of two perindopril salts. Evaluation of the interaction with HPLC and ESI LC/MS methods. <i>Acta Poloniae Pharmaceutica</i> , 2018, 75, 1117-1125. | 0.3 | 0 |
| 15 | How to stabilize cilazapril-containing solid dosage forms? The optimization of a final drug formulation. <i>Arabian Journal of Chemistry</i> , 2017, 10, 378-388. | 2.3 | 2 |
| 16 | Unknown face of known drugs – what else can we expect from angiotensin converting enzyme inhibitors?. <i>European Journal of Pharmacology</i> , 2017, 797, 9-19. | 1.7 | 13 |
| 17 | Thermo-, Radio- and Photostability of Perindopril Tert-butylamine in The Solid State. Comparison to Other Angiotensin Converting Enzyme Inhibitors. <i>Iranian Journal of Pharmaceutical Research</i> , 2017, 16, 1007-1018. | 0.3 | 2 |
| 18 | COX-2 inhibitors: a novel strategy in the management of breast cancer. <i>Drug Discovery Today</i> , 2016, 21, 598-615. | 3.2 | 76 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Determination of the Juglone Content of <i>Juglans regia</i> Leaves by GC/MS. Natural Product Communications, 2015, 10, 1934578X1501000. | 0.2 | 4 |
| 20 | Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors. Current Pharmaceutical Design, 2015, 21, 1764-1775. | 0.9 | 41 |
| 21 | How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor. Drug Discovery Today, 2014, 19, 1731-1743. | 3.2 | 23 |
| 22 | The mutagenicity analysis of imidapril hydrochloride and its degradant, diketopiperazine derivative, nitrosation mixtures by in vitro Ames test with two strains of Salmonella typhimurium. Reports of Practical Oncology and Radiotherapy, 2014, 19, 412-419. | 0.3 | 4 |
| 23 | Cilazapril decomposition kinetics and mechanism in the solid state versus stability of the other ester pro-drug angiotensin converting enzyme inhibitors. Reaction Kinetics, Mechanisms and Catalysis, 2013, 109, 285-300. | 0.8 | 8 |
| 24 | Optimization of Storage and Manufacture Conditions for Imidapril Hydrochloride in Solid State as a Way to Reduce Costs of Antihypertensive Therapy. AAPS PharmSciTech, 2013, 14, 1199-1208. | 1.5 | 13 |
| 25 | Kinetics and mechanism of solid state imidapril hydrochloride degradation and its degradation impurities identification. Open Chemistry, 2013, 11, 754-762. | 1.0 | 3 |
| 26 | Is there any association between imidapril hydrochloride stability profile under dry air conditions and cancer initiation?. International Journal of Pharmaceutics, 2013, 456, 332-339. | 2.6 | 7 |
| 27 | Effect of pharmaceutical excipients on the stability of angiotensin-converting enzyme inhibitors in their solid dosage formulations. Drug Development and Industrial Pharmacy, 2013, 39, 51-61. | 0.9 | 18 |
| 28 | The Renin-angiotensin System as a Target of Novel Anticancer Therapy. Current Pharmaceutical Design, 2013, 19, 7103-7125. | 0.9 | 18 |
| 29 | Kinetics of degradation of imidapril hydrochloride in finished dosage formulations. Acta Poloniae Pharmaceutica, 2013, 70, 737-42. | 0.3 | 8 |
| 30 | Cilazapril stability in the presence of hydrochlorothiazide in model mixtures and fixed dose combination. Acta Poloniae Pharmaceutica, 2013, 70, 1079-85. | 0.3 | 1 |
| 31 | First order derivative spectrophotometric and HPLC methods for determination of moexipril hydrochloride in the pure form, pharmaceutical formulations and evaluation of its stability. Acta Poloniae Pharmaceutica, 2012, 69, 389-95. | 0.3 | 1 |
| 32 | UV derivative spectrophotometric and RP-HPLC methods for determination of imidapril hydrochloride in tablets and for its stability assessment in solid state. Acta Poloniae Pharmaceutica, 2011, 68, 645-51. | 0.3 | 10 |
| 33 | Validation of HPLC method for determination of atorvastatin in tablets and for monitoring stability in solid phase. Acta Poloniae Pharmaceutica, 2006, 63, 471-6. | 0.3 | 25 |
| 34 | Kinetics of Lisinopril degradation in solid phase. Reaction Kinetics and Catalysis Letters, 2005, 85, 145-152. | 0.6 | 9 |
| 35 | The influence of pharmaceutical excipients on quinapril hydrochloride stability. Acta Poloniae Pharmaceutica, 2005, 62, 189-93. | 0.3 | 13 |
| 36 | The influence of relative humidity and temperature on stability of moexipril hydrochloride in solid phase. Acta Poloniae Pharmaceutica, 2004, 61, 91-6. | 0.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Kinetics of degradation of enalapril maleate in dosage forms. <i>Acta Poloniae Pharmaceutica</i> , 2004, 61, 415-8. | 0.3 | 5 |
| 38 | Evaluation of stability of enalapril maleate in solid phase. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 31, 375-380. | 1.4 | 38 |
| 39 | The stability of quinapril hydrochloride—a mixture of amorphous and crystalline forms (QHCl-AC)—in solid phase. <i>Acta Poloniae Pharmaceutica</i> , 2003, 60, 443-9. | 0.3 | 11 |
| 40 | Kinetics of hydrolysis of tetrahydrozoline hydrochloride in aqueous solutions. <i>Reaction Kinetics and Catalysis Letters</i> , 2001, 74, 135-142. | 0.6 | 1 |